Vision
Improved health outcomes, improved experience, and reduced cost.
Mission
We are dedicated to helping critically ill patients wean from mechanical ventilation
Values

Patients Come First

We serve patients by providing the best possible products, training, support and services that substantially improve clinical outcomes and quality of life as well as reduce healthcare costs.

Respect for People

We provide a safe and respectful workplace that encourages creativity, open discussions and where accountability and diversity are highly valued. Humility is a virtue. We succeed together, not alone

Integrity

Honesty and integrity is at the center of all we do. Everyone is responsible for conducting our business in a fair and ethical manner, and for maintaining full compliance with all applicable laws and regulations. Careful stewardship of the resources entrusted to us by our shareholders is critical to our long-term success. Everyone is responsible for the cost-effective management of our business.

Innovation

Innovation is our lifeblood, whether it relates to our products, our services or the way we run our business. Each of us is responsible for improving what we touch and for doing so with a true sense of purpose.

Trust

We trust each other to uphold these values, to make well informed decisions, and to always work in the best interests of our stakeholders.

Get in touch

Corporate Headquarters

Lungpacer Medical Inc.
Suite 130, 601 W Cordova Street
Vancouver, B.C. V6B 1G1
Canada

USA

Lungpacer Medical USA Inc.
260 Sierra Drive, #116
Exton, PA 19341
USA


Emergency Use Indication:

The Lungpacer DPTS has been authorized for emergency use in healthcare settings for treatment of patients on invasive mechanical ventilation who are at high risk of weaning failure, including COVID-19 patients, during the COVID-19 pandemic.


Important Safety and Effectiveness Information:

There are no FDA approved, licensed, or cleared device treatments to assist in weaning patients off of ventilators. Based on bench testing and reported clinical experience, FDA has concluded that the Lungpacer DPTS may be effective at treating patients during COVID-19 by helping wean patients off ventilators in healthcare settings, thereby reducing their risks of prolonged mechanical ventilation and increasing the availability of ventilators during the COVID-19 pandemic.

Lungpacer DPTS treatment is for a maximum of 30 days. Device-related serious adverse events reported in clinical trials were single events of pneumothorax and mucus plug liberation.

The LIVE Catheter component of the Lungpacer system has not been evaluated for safety when used with cardiac pacemakers or defibrillators and should be removed prior to Magnetic Resonance (MR) imaging. Duration: The Lungpacer DPTS is available under an Emergency Use Authorization for the duration of the COVID-19 pandemic.

Emergency Use Instructions for Use, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients are available at: http://lungpacer.com/emergency-use-authorization.

For more information visit https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations.



Emergency Use Authorization Information:

This Diaphragmatic Pacing Stimulator has not been FDA cleared or approved.

This Diaphragmatic Pacing Stimulator has been authorized by FDA under an Emergency Use Authorization (EUA).

This Diaphragmatic Pacing Stimulator is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Diaphragmatic Pacing Stimulator Systems under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.